320
Participants
Start Date
May 31, 2026
Primary Completion Date
February 29, 2028
Study Completion Date
August 31, 2028
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
IFC will be administered based on the study site's assigned treatment block. Study subjects will receive IFC with a point-of-care testing value of FCS \<1.6 hPa. Additional IFC may be administered per point-of-care testing or clinical judgement, as needed.
Cryoprecipitated-Antihemophilic Factor
Cryo-AHF will be administered based on the study site's assigned treatment block. Study subjects will receive Cryo-AHF with a point-of-care testing value of FCS \<1.6 hPa. Additional Cryo-AHF may be administered per point-of-care testing or clinical judgement, as needed.
University of Maryland School of Medicine, Baltimore
Jackson Memorial Hospital, University of Miami, Miami
Barnes-Jewish Hospital, Washington University of Saint Louis, St Louis
University of Colorado, Anschutz Medical Center, Aurora
Lead Sponsor
Coalition for National Trauma Research
OTHER
Cerus Corporation
INDUSTRY